We have developed a unique corporate structure to develop our broad pipeline of oncology drug candidates. This corporate structure involves the formation of joint venture partnerships for select products in various territories to optimize our development efforts and corporate funding.
Our joint ventures have independent management and substantially independent funding sources, which allows each of our companies to focus on the development of their respective product candidates.
Our joint ventures include:
Panacela Labs, Inc., formed in 2011 to develop new preclinical product candidates, primarily focused in oncology.
Incuron, LLC - In 2015, CBLI divested its interest in Incuron, LLC, which was formed in 2010 to develop CBL0137 and its predecessor. CBLI retains a royalty on the future commercialization, licensing or sale of the CBL0137 technology and future change of control transaction of Incuron.
http://www.cbiolabs.com/subsidiaries
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM